Lynn Thomason, Ph.D.
Dr. Thomason has extensive knowledge of microbial genetics. She uses recombineering to generate genetically modified genomes for functional genomic studies, as well as investigating the molecular mechanism of recombineering. Dr Thomason is a group leader for the Basic Sciences Program (Leidos Biomedical, Inc.), mentors technicians, postdocs and summer students in MCG, attends and presents in MCG and GRCBL group meetings and other scientific meetings, assists other scientists, and publishes experimental results.
microbial genetics, recombineering: in vivo genetic engineering, viral-host interactions, Escherichia coli, bacteriophage λ
Positive and negative selection using the tetA-sacB cassette: recombineering and P1 transduction in Escherichia coli.Nucleic Acids Res.. 41: e204, 2013. [ Journal Article ]
- Curr Protoc Mol Biol. 106: 1.16.1-1.16.39, 2014. [ Journal Article ]
Examining a DNA Replication Requirement for Bacteriophage λ Red- and Rac Prophage RecET-Promoted Recombination in Escherichia coli..MBio. 7(5): e01443-16, 2016. [ Journal Article ]
Evidence that bacteriophage λ lysogens may induce in response to the proton motive force uncoupler CCCP.[ Journal Article ]
- Nat Protoc. 4: 206-23, 2009. [ Journal Article ]
Lynn Thomason obtained an undergraduate degree in general studies in the physical sciences (1983) and a provisional teaching certificate (1984), both from Washington State University. She earned both a M.S. (1987) and a Ph.D. (1993) from the Department of Chemistry at the University of Oregon, where she was a graduate student in the laboratory of Dr. Franklin W. Stahl in the Institute of Molecular Biology. Her thesis work demonstrated that, under some conditions, bacteriophage lambda circular monomer chromosomes are packaged in vivo. After additional time in the Stahl laboratory, in 1998 Lynn became a postdoctoral fellow in the laboratory of Dr. Richard Calendar at University of California at Berkeley where, in collaboration with Dr. David Ow of the Agricultural Research Service of the U.S. Department of Agriculture, she demonstrated activity of the bacteriophage PhiC31 site-specific recombination system in the fission yeast Schizosaccharomyces pombe. In 2001 Dr. Thomason came to the National Cancer Institute at Frederick as a cancer research award (CRTA) trainee in Dr. Donald Court’s lab, where she learned recombineering and helped further develop the technology. After completion of the CRTA program Lynn remained in Dr. Court's lab and is presently employed as a scientist II by Leidos Biomedical, Inc.